When your focus is Biotherapeutics, QPS’ Global Laboratories provide a full range of bioanalytical solutions to support immunogenicity evaluations during drug development from discovery through clinical development and filing.
Sponsored by Waters, Bioanalysis Zone explored the analysis of antibody drug conjugates (ADCs), the unique bioanalytical challenges they pose, and how those challenges are being addressed.
GVK Biosciences (GVK BIO) offers screening services for drug discovery to determine biological activity and properties customized to meet the research needs of the Pharma and Biotech industries. Our range of assays include Biochemical, Cellular, ADME assays & Animal models for profiling of NCEs for Potency, Selectivity, Efficacy, Drugability and Toxicity.
An overview of our Technology Accelerator business model. We describe a hybrid model leveraging minimally-dilutive funding and experienced pharmaceutical management to “de-risk” and drive projects to IND. Our area of expertise is prodrugs and infectious diseases (www.tsrlinc.com).
Here you can easily find RAC US Exam Questions along with huge discount and money back guarantee. We provide you RAC US Real Exam Questions. Get the file and pass your exam in one day.
https://www.certs4you.com/raps/rac-us-dumps.html
Sponsored by Waters, Bioanalysis Zone explored the analysis of antibody drug conjugates (ADCs), the unique bioanalytical challenges they pose, and how those challenges are being addressed.
GVK Biosciences (GVK BIO) offers screening services for drug discovery to determine biological activity and properties customized to meet the research needs of the Pharma and Biotech industries. Our range of assays include Biochemical, Cellular, ADME assays & Animal models for profiling of NCEs for Potency, Selectivity, Efficacy, Drugability and Toxicity.
An overview of our Technology Accelerator business model. We describe a hybrid model leveraging minimally-dilutive funding and experienced pharmaceutical management to “de-risk” and drive projects to IND. Our area of expertise is prodrugs and infectious diseases (www.tsrlinc.com).
Here you can easily find RAC US Exam Questions along with huge discount and money back guarantee. We provide you RAC US Real Exam Questions. Get the file and pass your exam in one day.
https://www.certs4you.com/raps/rac-us-dumps.html
When your focus is small molecules, biomarkers, or protein biotherapeutics,
QPS’ LC-MS/MS laboratories provide a full range of
bioanalytical solutions to support drug development
from discovery through clinical development.
Functional Predictions and Conservation Scores in VSClinicalGolden Helix
Computational evidence plays a vital role in the interpretation of variants using the ACMG guidelines. This includes functional prediction scores like SIFT and PolyPhen2, as well as conservation metrics such as GERP++ and PhyloP. In this webcast, we review the conservation scores and functional prediction algorithms available in VSClinical. This includes a discussion of our own implementation of these algorithms, along with a comparison to more recent variant prediction methods.
Innovative Solutions to Advance Immune-Mediated Inflammatory Disease Drug Dev...Covance
Recent scientific advances have propelled our understanding of the immune system's regulation, as well as identified targets that play key roles in inflammatory and autoimmune diseases. Immune-Mediated Inflammatory Diseases (IMIDs) share common pathways, creating the opportunity to treat multiple inflammatory diseases and improve treatment for millions of people worldwide.
Canvax Catalog 2017 - Accelerating your Molecular Biology DiscoveriesJesús C. Morales
Canvax Biotech is a leading spanish manufacturer and supplier of of 450+ high quality, cost-effective and easy-to-use Highly Innovative Molecular Biology solutions, services, kits and R&D Reagents that accelerates Scientists Success since 2001.
What we manufacture?
>> DNA Cloning >> Mammalian & Bacterial Expression vectors >> GPCR cDNA ORF Clones >> PCR Essentials
>> Cell based assay and molecule detection kits >> DNA & RNA Purification Kits >> Recombinant proteins
Cell & Gene Therapy Clinical Development SolutionsCovance
Cell & Gene Therapy clinical development solutions to reduce scientific, regulatory and commercial risks, and accelerate development wherever you are in your product's development.
The purpose of this review is to provide veterinarians with key facts and information relevant to serological testing of individual dogs and cats in the clinical setting. Specifically, this paper addresses the role of antibody testing for the core, vaccine-preventable diseases canine distemper virus, canine and feline parvovirus, and canine adenovirus.
Bioanalytical Method Development and Validation of Biosimilars: Lessons LearnedSai Babitha
Biosimilars are expected to be a significant growth driver for the pharmaceutical industry over the next decade, mainly because of the current market penetration of biologics and the need to provide payers cost savings over the originator therapeutics. Legislative support and regulatory guidance have facilitated their entry into pharmacy formularies of the future. Unlike small molecule generic drugs, biosimilars are heterogeneous proteins manufactured using cell-based systems of either microbial or mammalian origin. The use of living systems to manufacture drugs raises challenges in terms of product characterization and therapeutic equivalence to the innovator protein therapeutic. In this article, we share some lessons learned from developing
and validating pharmacokinetic and immunogenicity assays that support preclinicaland clinical comparative studies for the development of biosimilars.
Cell & Gene Therapy Clinical Development SolutionsCovance
Cell & Gene Therapy clinical development solutions to reduce scientific, regulatory and commercial risks, and accelerate development wherever you are in your product's development.
This presentation mainly deals with clinical development of biosimilar products. It also gives enough on non-clinical development so that the audience is well oriented.
QPS DMPK provides a dedicated team of senior scientists to help select, design and conduct the appropriate ADME studies
for your specific compounds and therapeutic targets.
Working with QPS DMPK is a collaborative and consultative
endeavor that also incorporates our operational effectiveness
and dedication to customer service.
When your focus is small molecules, biomarkers, or protein biotherapeutics,
QPS’ LC-MS/MS laboratories provide a full range of
bioanalytical solutions to support drug development
from discovery through clinical development.
Functional Predictions and Conservation Scores in VSClinicalGolden Helix
Computational evidence plays a vital role in the interpretation of variants using the ACMG guidelines. This includes functional prediction scores like SIFT and PolyPhen2, as well as conservation metrics such as GERP++ and PhyloP. In this webcast, we review the conservation scores and functional prediction algorithms available in VSClinical. This includes a discussion of our own implementation of these algorithms, along with a comparison to more recent variant prediction methods.
Innovative Solutions to Advance Immune-Mediated Inflammatory Disease Drug Dev...Covance
Recent scientific advances have propelled our understanding of the immune system's regulation, as well as identified targets that play key roles in inflammatory and autoimmune diseases. Immune-Mediated Inflammatory Diseases (IMIDs) share common pathways, creating the opportunity to treat multiple inflammatory diseases and improve treatment for millions of people worldwide.
Canvax Catalog 2017 - Accelerating your Molecular Biology DiscoveriesJesús C. Morales
Canvax Biotech is a leading spanish manufacturer and supplier of of 450+ high quality, cost-effective and easy-to-use Highly Innovative Molecular Biology solutions, services, kits and R&D Reagents that accelerates Scientists Success since 2001.
What we manufacture?
>> DNA Cloning >> Mammalian & Bacterial Expression vectors >> GPCR cDNA ORF Clones >> PCR Essentials
>> Cell based assay and molecule detection kits >> DNA & RNA Purification Kits >> Recombinant proteins
Cell & Gene Therapy Clinical Development SolutionsCovance
Cell & Gene Therapy clinical development solutions to reduce scientific, regulatory and commercial risks, and accelerate development wherever you are in your product's development.
The purpose of this review is to provide veterinarians with key facts and information relevant to serological testing of individual dogs and cats in the clinical setting. Specifically, this paper addresses the role of antibody testing for the core, vaccine-preventable diseases canine distemper virus, canine and feline parvovirus, and canine adenovirus.
Bioanalytical Method Development and Validation of Biosimilars: Lessons LearnedSai Babitha
Biosimilars are expected to be a significant growth driver for the pharmaceutical industry over the next decade, mainly because of the current market penetration of biologics and the need to provide payers cost savings over the originator therapeutics. Legislative support and regulatory guidance have facilitated their entry into pharmacy formularies of the future. Unlike small molecule generic drugs, biosimilars are heterogeneous proteins manufactured using cell-based systems of either microbial or mammalian origin. The use of living systems to manufacture drugs raises challenges in terms of product characterization and therapeutic equivalence to the innovator protein therapeutic. In this article, we share some lessons learned from developing
and validating pharmacokinetic and immunogenicity assays that support preclinicaland clinical comparative studies for the development of biosimilars.
Cell & Gene Therapy Clinical Development SolutionsCovance
Cell & Gene Therapy clinical development solutions to reduce scientific, regulatory and commercial risks, and accelerate development wherever you are in your product's development.
This presentation mainly deals with clinical development of biosimilar products. It also gives enough on non-clinical development so that the audience is well oriented.
QPS DMPK provides a dedicated team of senior scientists to help select, design and conduct the appropriate ADME studies
for your specific compounds and therapeutic targets.
Working with QPS DMPK is a collaborative and consultative
endeavor that also incorporates our operational effectiveness
and dedication to customer service.
Whether your focus is on small molecules, proteins, bio-therapeutics, vaccines, or gene therapy, QPS provides a full range of bioanalytical solutions to support drug development from discovery through clinical development and filing.
At QPS, translational medicine brings together leading-edge technologies and pharmaceutical research and development experience to create a business service unit that works efficiently to advance your drug development program.
Our profound expertise in Neuroscience and two decades of experience in contract research result in a sustainable advantage for our customers. QPS offers you a sophisticated range of validated transgenic and non-transgenic in vivo and in vitro models to guarantee that your new chemical or biological compounds are profiled in depth.
The QPS Bioanalysis General presentation is a summary of our capabilities in Neuropharmacology, Toxicology, DMPK, Bioanalytical, Translational Medicine, and Dermal and Transdermal Preclinical services.
At QPS, CSF Sampling brings together leading-edge technologies and pharmaceutical research and development to reveal pharmacokinetic information about drug concentrations.
Partnering with QPS for a well-conceived and executed IND-enabling preclinical program will provide you with a detailed
assessment of your drug candidate and the most agile, flexible and timely pathway to filing an IND.
QPS Missouri's Negative Pressure Room.
A negative pressure room uses lower air pressure than the
rooms surrounding it to allow outside air into the facility.
This traps and keeps harmful particles from leaving the
potentially contaminated area.
A well-conceived and executed preclinical and clinical
radiolabeled ADME program will provide you with a detailed
assessment of the total fate (mass balance, route, and rate of excretion,
tissue distribution, metabolic pathways, and identity and quantity of
metabolites) of your drug candidate to support regulatory submissions.
QPS Regulated Bioanalysis of Antibody Drug ConjugatesQPS Holdings, LLC
PK profiling reflects molecular complexity. Since 2001 QPS’ bioanalytical teams have contributed to ADC drug development,
supporting the filing of one of the first drug targeting
programs and continue to develop customized
strategies for novel conjugate molecules.
To support research and development in different stages of biopharmaceutical compounds and products, QPS offers biomarker services in different global competence centers using
a wide range of technology platforms to support programs in any therapeutic area. QPS biomarker capabilities range from small molecule analysis to whole cell characterization.
This white paper focuses on overcoming the challenges of participating in a pediatric trial. One of the biggest issues is that it is difficult to enroll participants in pediatric trials. Read these 5 strategies to help make it easier to enroll trial participants and complete successful trials.
In recent years, the pharmaceutical industry has witnessed increased political interest and attention due to the increased recognition of the economic importance and financial impact of healthcare as a component of national budgets. Biologic drugs (biologics) have attracted the attention of politicians since biologics have moved out of the niche pharmaceutical arena to contribute 17% of global pharmaceutical sales, representing revenues of more than $120bn in 2009. The market for biologics is growing at twice the rate of pharmaceutical drugs, placing significant cost pressures on government, employers, insurers, and patients. Government and insurers are using several strategies to contain costs but must ensure that the financial burden placed on patients does not restrict access to the health care system. Establishing a regulatory pathway for ‘follow-on’ biologics (biosimilars) was therefore felt to be necessary by many stake holders to encourage competition and reduce prices. Many pharmacutical companies both large and small - are expecting their bottom line growth to be driven by biosimilars and are channeling their R&D budgets to compete in what – according to many - is going to be one of the hottest areas in a radically changing global pharmaceutical market.
Three Lessons to Help Accelerate Pharmaceutical Breakthroughs for CNS DisordersQPS Holdings, LLC
"Developing therapies for diseases of the central nervous system (CNS) presents special challenges directly related to the complexity of the human brain and its function of integrating our communications with the outside world. Animal models of human neurological and psychiatric disorders are scarce, because many of these human diseases do not naturally occur in animals, and their study necessitates either specific manipulation (induced models) or the production of genetically modified rodents (transgenic and KO models). Even with these models, it remains unclear, what behavioral domain really resembles higher brain function in humans, and how we can interpret animal data on cognition, emotion, social interaction or activities of daily living.
Furthermore, in contrast with other organs, the CNS is sequestered from the general circulation by the blood brain barrier (BBB), potentially preventing many compounds from reaching their intended target. Quantifying how much of and how long a compound resides in the CNS is difficult and indirect. Therefore, the assessment of target engagement calls for specific techniques and know-how. While animal models provide some information as to how well a given compound accesses the brain, this data cannot always be translated directly to humans. Insufficient knowledge of target-compound interaction may be a major cause of failure in drug development for CNS disorders.
QPS understands the specific challenges of translation from animal models to human clinical application. Our extensive experience in CNS affords us a clear view of its complexities and its current global clinical study environment. Our direct links with the international scientific community and close relationships with key opinion leaders worldwide, together with our dedicated experts, original strategies and operational transparency, are keys to the effective execution of CNS programs for our clients."
The Nobel Prize for the discovery that double-stranded RNAs (dsRNAs) can trigger silencing of complementary messenger RNA sequences was awarded in 1998 and the term ‘RNA interference’ (RNAi) was born, opening the door to a completely novel and untapped market within the pharmaceutical industry. Shortly thereafter, short dsRNAs — or short interfering RNAs (siRNAs) — were generated artificially and used to demonstrate that this process also occurs in mammalian cells. The knowledge that small strands of RNAs can affect gene expression has had a tremendous impact on basic and applied research, and RNAi is currently one of the most promising new approaches for disease therapy. In 2004, only six years after the discovery of RNAi, the first siRNA-based human therapeutics — developed to treat wet age-related macular degeneration — entered phase I clinical trials. RNAi is one of the fastest advancing fields in biology, and the flow of discovery gives true meaning to the expression ‘from the bench to the bedside'.
Sometimes practical or ethical considerations dictate whether healthy volunteers or patients should be recruited for a particular study. But there are usually sound scientific arguments for collecting PK data from actual patients, to supplement or substitute for PK data obtained from human healthy volunteers during the first phases of drug development. Knowing to what extent the results obtained in healthy volunteers – if available - can be extrapolated to the intended treatment population is critical. The US FDA has recognized the importance of PK studies for determining drug concentration-time profiles in target patient populations.
This white paper focuses on the 505(b)(2) New Drug Approval (NDA) regulatory pathway, which relies on the public literature of clinical studies and/or the FDA's filing of safety and efficacy data for a previously approved drug.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
1. TIME IS OF THE ESSENCE IN DRUG DEVELOPMENT.
CONTACT THE QPS BUSINESS DEVELOPMENT TEAM TODAY!
CALL +1 512 350 2827 EMAIL infobd@qps.com
WHEN YOUR FOCUS IS BIOTHERAPEUTICS,
QPS’ Global Laboratories provide a full range of
bioanalytical solutions to support immunogenicity
evaluations during drug development from discovery
through clinical development and filing.
A flexible approach to
Immunogenicity
2. Immunogenicity
While Biotherapeutic drugs
such as monoclonal antibodies
(mAbs), recombinant proteins and
oligonucleotides are emerging
treatments for diseases, they may
illicit an immune response in
the form of anti-drug-antibodies
(ADA) resulting in potential
reductions in efficacy, and
sometimes, safety concerns. As
such, immunogenic potential
needs to be assessed.
QPS is a Global CRO with state-
of-the-art bioanalytical facilities
and immunogenicity testing
laboratories strategically located
in the United States (Delaware)
and Europe (The Netherlands).
QPS first implemented ADA
analysis for proteins and mAbs
in 2003 and of oligonucleotides
as early as 2013. Since that time
our laboratories have performed
≥700 regulated ADA studies
supporting over 150 biologic drug
development programs.
QPS is an expert in nAb testing
and since 2002 we have applied
our extensive knowledge
and application of new assay
technologies to over 60 programs.
Method Development
and Optimization
With the knowledge that the
evaluation of ADAs is often a
multi-step analytical approach
with differing assay formats and
platforms, QPS offers custom
method development and
optimization.
Method development at QPS can
involve antibody enrichment and
sample pretreatment techniques
to improve assay sensitivity and
drug tolerance or to reduce target
interference:
f Affinity capture elution
(ACE) and SPEAD (Solid-
phase Extraction with Acid
Dissociation)
f Critical Reagent labeling
(biotin and sulfo-tag, etc.)
Assay Optimization:
f Drug Tolerance
f Target Interference
f Sensitivity
f Specificity
f Precision
www.qps.com infobd@qps.com +1 512-350-2827
3. AGILITY. FLEXIBILITY. SPEED.
Immunogenicity
Monitoring ADA &
nAb
ADA capabilities:
f Screening, confirmation and
titering by ELISA or MSD
Electrochemiluminescence
(MESO SECTOR S 600)
• Screening for positive
responses in study samples
• Confirmation test for
samples displaying positive
responses during screening
f Titering of confirmed positive
samples to determine the
relative degree of antigenicity
f On staff statistician for cut-
point analysis
f Domain confirmation to
bispecific therapeutic drugs
nAb capabilities:
f Screening
f Titer assessment (quasi-
quantification)
f Competitive ligand binding
assay or cell-based neutralizing
antibody detection
f Cell banking and maintanance
Data Quality is Key
Our laboratories are Good
Laboratory Practice (GLP)
compliant/certified since 2002
and for Clinical Bioanalysis Good
Clinical Practice (GCP) standards
are embedded within our GLP
Quality systems. Our robust
methods are fully validated in
compliance with the FDA and
EMA guidelines.
Our Experts at the QPS Labs in Delaware, USA and
Groningen, The Netherlands
are Ready to Support Your Next ADA & nAb Project
4. WWW.QPS.COM
Fargo, ND, USA
Dermal and Transdermal
Research Laboratory (DTRL)
Groningen and Leeuwarden,
The Netherlands
Bioanalysis (BA)
Clinical Research Services (CRS)
Translational Medicine (TLM)
Suzhou and Shanghai,
China
Bioanalysis (BA)
Clinical Research Services (CRS)
Miami, FL, USA
Clinical Research
Services (CRS)
Hyderabad, India
Bioanalysis (BA)
Clinical Research
Services (CRS)
Taipei, Taiwan
Bioanalysis (BA)
Clinical Research Services (CRS)
Toxicology (TOX)
Newark, DE, USA
Bioanalysis (BA)
Clinical Research Services (CRS)
DMPK
Translational Medicine (TLM)
Global Headquarters for
QPS Holdings LLC
Graz, Austria
Clinical Research Services (CRS)
DMPK
Histology Services
Neuropharmacology
Rare Disease
Rodent Biobank
Springfield, MO, USA
Clinical Research
Services (CRS)
QPS is a Global CRO
with locations around the world
to serve the evolving needs of the
Pharmaceutical and Biotech industries
Immunogenicity
CALL +1 512 350 2827
EMAIL infobd@qps.com